AC Immune S.A. (ACIU): Market Cap to Revenue Ratio
AC Immune's authority in targeted therapy is validated by partnerships with industry behemoths. The business valuation based on P/S demonstrates the dynamics of this confidence, where the value 8.70 reflects the metric's balance. High capital expenditures and patent protection create a steep barrier to entry. Meanwhile, the Morphomer platform ensures pricing power through the development of unique antibodies to combat Alzheimer's.
Analytical breakdowns for AC Immune Corp (ACIU)
- stock value and consensus price forecast:
- stock exchange capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
- earnings and multiples data:
ACIU - Net Income|Projected Future Earnings AC Immune|ACIU - Price to Earnings Ratio|Future Price to Earnings Multiple AC Immune S.A.|ACIU - Price/Earnings to Growth Ratio|Company Value to EBITDA AC Immune Corp|ACIU - Operating profit EBITDA|Net earnings per share (EPS TTM) AC Immune|ACIU - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months acimmune.com|ACIU - Net earnings per share growth this year|Expected earnings per share trend next year AC Immune
- issuer revenue and sales details:
Summary company analytics:ACIU acimmune.com
The multiple is calculated as the ratio of the current market capitalization of all shares to the total annual revenue, measuring the premium the market is willing to pay per unit of sales. Under tight monetary policy conditions, this price-to-sales ratio reflects the valuation of AC Immune (ACIU) and its potential in neurodegenerative disease therapies, where balance sheet stability is maintained through strategic payments from global partners.
Competitors of AC Immune
P/S Multiple biogen.com (BIIB)|Price-to-Revenue Ratio Neurocrine Biosciences, Inc. NBIX|RGC: Market Cap to Revenue Ratio|Axsome Therapeutics Inc - P/S Multiple|Price to Sales ACADIA Corp|XENE: P/S Multiple|vikingtherapeutics.com (VKTX) - P/S Multiple|SUPN (Supernus) - P/S Multiple|Market Cap to Revenue Catalyst Pharma (CPRX)|P/S Multiple DNLI|Price-to-Revenue Coefficient Harmony Corp|Biohaven Ltd. - Market Cap to Revenue|P/S Multiple amylyx.com AMLX|TRVI - Price-to-Revenue Ratio|PRAX (Praxis Precision Medicines Inc) - Market Cap to Revenue Ratio|AVXL: P/S Multiple|Price to Sales CeriBell EEG (CBLL)|Market Cap to Revenue PRTA|P/S Multiple Alector Therapeutics|Price-to-Revenue Ratio Annexon (ANNX)|OMER (omeros.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Neurogene Corp NGNE|Voyager Corp (VYGR) - Price to Sales|Neumora Therapeutics - P/S Multiple|SCLX - P/S Multiple|TVGN: P/S Multiple|Market Cap to Revenue Alpha Cognition Inc.|Market Cap to Revenue CGTX|IKT: Market Capitalization-to-Revenue Ratio|P/S Multiple SAVA|Price-to-Revenue Coefficient assertiotx.com|Price-to-Revenue Ratio Coya Therapeutics COYA|VTGN - Market Cap to Revenue|OVID - Price-to-Revenue Ratio|Acumen Pharmaceuticals, Inc (ABOS) - Market Cap to Revenue|CRVO (CervoMed Inc.) - Market Cap to Revenue|Alterity Therapeutics Limited (ATHE) - P/S Multiple|Price-to-Revenue Ratio Clene Inc|Market Cap to Revenue Ratio PEPG (PepGen Corp)|P/S Multiple JUNS|RLMD - Price to Sales|P/S Multiple ANVS (Annovis Bio, Inc.)|P/S Multiple Grace Therapeutics Inc GRCE|Firefly Neuroscience - P/S Multiple|Klotho Neurosciences Inc (KLTO) - Market Cap to Revenue|NRSN: P/S Multiple|RVPH - Price-to-Revenue Coefficient|Market Cap to Revenue MTVA|P/S Multiple neuraxis.com|Price-to-Revenue Ratio Helius Medical (HSDT)|passagebio.com - Market Cap to Revenue Ratio|P/S Multiple NEUP (Neuphoria Therapeutics)|Minerva (NERV) - Price to Sales|ATHA: Market Cap to Revenue|ADXN - P/S Multiple|alzamend.com (ALZN) - Price-to-Revenue Ratio|Cyclerion Therapeutics, Inc. - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Protagenic Therapeutics Inc.|Price to Sales Pasithea KTTA|P/S Multiple CRGT|P/S Multiple avenuetx.com (ATXI)|P/S Multiple BCLI (BrainStorm Cell Therapeutics)|CARA - Market Cap to Revenue|CHRO: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ELYM (Eliem Therapeutics)|ITCI: P/S Multiple|LBPH - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Marinus Pharmaceuticals, Inc.|Market Cap to Revenue NKGen Biotech Inc (NKGN)|Price-to-Revenue Ratio NeuroBo (NRBO)|Market Cap to Revenue Sage Therapeutics Inc SAGE|Synaptogenix, Inc. - Market Cap to Revenue|P/S Multiple trevena.com TRVN|VIGL - Price-to-Revenue Ratio|WENA (anewmeds.com) - Market Cap to Revenue Ratio|CERE: P/S Multiple
